The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Health Canada Approves CT-P13 SC for RA; Plus Tofacitinib May Increase Cardiac & Cancer Risks

Health Canada Approves CT-P13 SC for RA; Plus Tofacitinib May Increase Cardiac & Cancer Risks

March 5, 2021 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Health Canada Approves Remsima SC for RA
In February, Heath Canada issued a notice of compliance for Remsima SC (CT-P13 SC), granting marketing authorization and approving the agent to treat adults with rheumatoid arthritis (RA) in combination with methotrexate. This subcutaneous (SC) formulation of intravenous Remsima (CT-P13), which is biosimilar to infliximab, has been shown to reduce the signs and symptoms of RA, inhibit the progression of structural joint damage and improve physical functioning in adults with moderate to severe active RA. Additionally, CT-P13 SC can be used as maintenance therapy following induction treatment with intravenous infliximab.1

You Might Also Like
  • Subcutaneous CT-P13 Injection Evaluated for Safety & Efficacy of in RA Patients
  • EU Approves Remsima SC, a Biosimilar to Infliximab
  • IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
Also By This Author
  • FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis

This approval was based on clinical evidence that demonstrated the clinical response to CT-P13 SC was comparable to that of intravenous CT-P13 for up to one year. Additionally, the study showed switching RA patients from the intravenous formulation to CT-P13 SC at week 30 was comparable to maintaining CT-P13 SC treatment for up to 54 weeks. No notable differences were found in the safety profiles of CT-P13 SC and intravenous CT-P13.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients using CT-P13 SC will have the opportunity to self-administer the medication at home rather than go to a physician’s office, clinic or infusion center. Patients may find this more convenient and time saving. The formulation has three administration options: an autoinjector (pre-filled pen), a pre-filled syringe or a pre-filled syringe with a needle safeguard.

Tofacitinib May Increase Cardiac & Cancer Risks
On Feb. 4, the U.S. Food and Drug Administration (FDA) alerted healthcare professionals and the public that patients using tofacitinib may be at increased risk of serious cardiac events and cancer compared with tumor necrosis factor (TNF) inhibitors. This announcement is based on the preliminary results of a safety trial of tofacitinib.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients should not stop taking tofacitinib without first consulting their healthcare team. Healthcare professionals should consider the benefits and risks of tofacitinib treatment when deciding whether to continue patients on or prescribe the agent.

Healthcare professionals should report any adverse events or side effects related to tofacitinib use to MedWatch, the FDA’s Safety Information and Adverse Event Reporting Program.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Celltrion Healthcare. News release: Celltrion Healthcare receives Health Canada marketing authorization for world’s first subcutaneous formulation of infliximab, Remsima SC, for the treatment of people with rheumatoid arthritis. 2021 Feb 1.
  2. U.S. Food & Drug Administration. Xeljanz, Xeljanz XR (tofacitinib): Drug safety communication—initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine. 2021 Feb 4.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Conditions Tagged With: Canada, CT-P13, Drug Safety, FDA, infliximab, Rheumatoid Arthritis (RA), Tofacitinib

You Might Also Like:
  • Subcutaneous CT-P13 Injection Evaluated for Safety & Efficacy of in RA Patients
  • EU Approves Remsima SC, a Biosimilar to Infliximab
  • IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
  • Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)